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ABSTRACT 
Aim: To analyse how healthcare utilisation, healthcare costs and health-related 
quality of life (HRQoL) differ for individuals with diabetes compared to control 
individuals from the general population and how these differences are associated with 
disease duration and changes in the health care over time. A further aim was to 
explore diabetes care from an equity perspective. 
Methods: The research was based on four cohorts with disease durations of 1, 8, 15 
or 24 years. These cohorts were selected from the Diabetes Incidence Study in 
Sweden, which registers all incident cases of diabetes in the age group 15 to 34 years, 
the majority Type 1 and insulin-treated. Control individuals were selected from the 
population register matched by age, sex and county of residence. In January 2008, a 
survey questionnaire was mailed by post to the 1983, 1992 and 1999 cohorts and their 
matching control groups. In 2009, the same survey questionnaire was quarterly sent 
to the 2008 cohort and to matching controls. The overall response rates were 54% 
(n=864) for individuals with diabetes and 51% (n=1616) for control individuals. 
Results: Higher utilisation of healthcare services by patients with diabetes compared 
to control individuals, and the necessary medication, led to an annual excess costs of 
40 000 to 50 000 Swedish crowns per patient with no significant differences among 
the four cohorts. The costs of health care for women (in both the diabetes groups and 
the control groups) were almost double the costs for men in most cohorts.  
Living with diabetes had a negative impact on HRQoL and the difference to control 
individuals increased by disease duration for women with diabetes. However, there 
were no significant differences between individuals with diabetes 1 year after diagnosis 
and the control individuals, which may be related to good early management of 
diabetes care and an early adaptation to the disease. 
Compared to a previous study conducted in the early 1990s, excess costs increased 
mainly due to the greater use of insulin pumps and insulin analogues. Utilisation 
patterns for patients with diabetes were stable except for a significant decrease in 
hospital inpatient care 1 year after diagnosis (60% to 13%), and an increase in daycare 
8 years after diagnosis (11% to 44%). The excess costs 1 year after diagnosis were 
similar whereas excess costs 8 years after diagnosis more than doubled, but while the 
largest proportion of costs in 2009 was for hospital outpatient care, 16 years earlier 
most costs were for hospital inpatient care. In line with the results from the previous 
study, the largest proportion of costs 8 years after diagnosis were attributable to insulin 
treatment and monitoring of blood glucose, followed by the costs for hospital outpatient 
care.  
Conclusions: Individuals with diabetes seem to lead rather unrestricted lives with less 
hospital inpatient care and a higher degree of self-management than 16 years earlier. 
However, the findings indicate that healthcare utilisation, costs and HRQoL vary by 
gender and socio-economic background. In addition to having diabetes, being a 
women, having a low education level or low income, and not being married all had a 
negative effect on almost all outcome measures addressed in this thesis.  
Utilisation patterns, costs and HRQoL can be described and analysed by continued 
health services research, and may be a valuable complement to more clinically oriented 
research. Health services research may also provide valuable information in the 
formulation of future healthcare policies. In contrast to randomised controlled trials, 
long-term studies of diabetes populations in real-world health systems can shed light on 
issues of access to the healthcare systems as well as on associated equity issues.  
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1 PROLOGUE 
 
I have had many windows of opportunities in my life. As time went by, these 
opportunities led me to where I am today with this thesis.  
 
My interest in health care began with the first window. While working temporarily at a 
staffing company I was sent to the Federation of Swedish County Councils (now the 
Swedish Association of Local Authorities and Regions). I was surprised to see how 
useful my background in studies in international management was. In collaboration 
with thoughtful and creative colleagues and healthcare professionals, I worked to 
improve Swedish healthcare. When the Federation offered me a job, I gladly accepted 
because it felt good to work in an area where I could contribute to society.  
 
After a few years of working in other areas, another window opened for me. I was 
contacted by Professor Mats Brommels, and met with him and Professor Göran 
Tomson. This meeting led to my employment at the Karolinska Institutet (KI), in the 
newly established Medical Management Centre (MMC). I was thrilled to be working 
again in the healthcare sector. My years at MMC have been both joyful and fruitful. I 
hope they will continue to be so. 
 
At KI, I worked with Dr. Pia Maria Jonsson on projects that investigated gender 
differences in patient safety and in the National Quality Registers. When Dr. Jonsson 
received funding from the Swedish Council for Working Life and Social Research for 
a follow-up of her thesis from 2001, another new window opened. Feeling excited 
about the possibility of digging deep into a research project, I enrolled as a PhD 
student and began the studies and research that have resulted in this thesis.  
 
My thesis title, As time goes by, has two implications. First, the title refers to the past 
three decades during which the management of diabetes developed mainly in three 
areas: advances in medical treatment; changes in level of care; and the increased role 
of the patient. Second, the title refers to the duration of diabetes that may affect how 
people with diabetes experience their disease.  
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2 DEVELOPMENTS IN HEALTH CARE AND IN THE 
MANAGEMENT OF DIABETES 
 
About 365,000 people in Sweden have diabetes, most of whom have Type 2 diabetes 
(1). About 15% of these people have Type 1 diabetes, which is the main diabetes 
examined in this thesis. After Finland, Sweden has the highest incidence rate of Type 1 
diabetes in the world (2).  
 
Type 2 diabetes, which is more common and is found in about 85% of people with 
diabetes, has a low incidence before the age of 30 years and increases markedly by 
age. Type 1 diabetes is an autoimmune disease in which the ability of the pancreas to 
produce insulin is low or non-existent. Type 1 diabetes, which usually begins before 
age 30, is a life-long disease, which is associated with risks of acute and long-term 
complications. In the following sections, the development of management of diabetes 
is explored from different health services perspectives. In this way, healthcare 
utilisation and changing utilisation patterns, the costs of diabetes and health-related 
quality of life (HRQoL) are explored. The study of diabetes from these perspectives 
reveals how the changes in the management of diabetes care have affected people with 
diabetes. The study also reveals how these perspectives are affected by the duration of 
the disease. This study has contributes to our understanding of how well Swedish 
diabetes care meets one of its major goals – equitable care for all patients. 
 
 
2.1 LONG-TERM COMPLICATONS AND MORTALITY 
Diabetes is a chronic disease that may affect people’s lifespan and their HRQoL. 
Individuals who receive a diagnosis of diabetes, especially Type 1 diabetes, often face a 
major upheaval in their lives. How they react to this diagnosis depends on how they 
generally react to difficulties in life and to their life situation at the time of diagnosis (3, 
4). In the early stages of diabetes, the focus is on achieving metabolic glucose control 
and teaching patients disease management. Chronic hyperglycaemia is accompanied 
with long-term microvascular (5) and macrovascular complications (6) both in Type 1 
and Type 2 diabetes. Because of these complications, people with diabetes, on average, 
have a shorter lifespan. Population-based studies in Sweden have found that age- and 
sex-standardised mortality is more than double in the first decades with the disease, 
mainly because of ketoacidosis (the shortage of insulin that makes the body burn fatty 
acids and produce acid ketones). Mortality after 10 years with diabetes is mostly caused 
by macrovascular disease and diabetic nephropathy (7). In the long-term, complications 
such as retinopathy, nephropathy, neuropathy and cardiovascular disease (described 
below) are likely to develop. 
 
Diabetic retinopathy occurs in both Type 1 and Type 2 diabetes and refers to the 
changes in the retinal vessels due to diabetes. These changes may lead to impaired 
vision and, in severe cases, to blindness. These risks increase with disease duration. 
However, through early diagnosis and treatment, the incidence of blindness and visual 
impairment among patients can be significantly reduced (8, 9). 
 
 
 
 
  3 
 
The most serious complication and leading cause of death among individuals with 
diabetes is nephropathy. Diabetic nephropathy, which is a pathological change in the 
kidneys, is the most common reason for dialysis or kidney transplants in Sweden. Prior 
to modern treatment, the highest incidence (5% per year) occurred after 15 to 20 years 
or disease duration. Today, the highest incidence (less than 2%) is seen after 25 to 30 
years (10).  
 
Neuropathy, defined as pathological changes in the peripheral nerves, may be one of 
the most common complications resulting from diabetes. Its prevalence is estimated at 
around 10% in patients at the onset of diabetes and at more than 50% in patients with 
longer disease duration. Although usually not life-threatening, neuropathy may lead to 
a significant reduction in the quality of life as many natural functions such as 
gastrointestinal disturbances and circulation may be affected. Patients may also 
experience problems with their blood pressure and sex life. There is a correlation 
between disease duration and the development of polyneuropathy (i.e., neuropathy 
affecting several nerves simultaneously); the longer someone has had diabetes, the 
more frequently peripheral polyneuropathy develops (11).  
 
Diabetes also increases the risk of macrovascular complications, which are almost 
identical with atherosclerosis seen in patients without diabetes. These cardiovascular 
diseases include ischemic heart disease, stroke and peripheral vascular disease. 
Individuals with diabetes have a greater likelihood than individuals without diabetes for 
another heart attack or stroke. Peripheral atherosclerosis is a common reason for 
amputation when foot ulcers do not heal (12). 
 
The average lifespan is shorter for people with Type 1 diabetes because of both acute 
and chronic complications associated with the disease. Early mortality is mainly related 
to ketoacidosis (13). Suicide, caused by psychosocial factors (7), is the primary reason 
for excess mortality among those with diabetes onset between the ages of 15 and 34 
years. Most excess late mortality, after a disease duration of 20 years, has been related 
to cardiovascular disease and nephropathy (14-16). 
 
 
2.2 DEVELOPMENTS IN THE MANAGEMENT OF DIABETES 
In 1993, researchers at the Stockholm Diabetes Intervention Study (17) and the 
Diabetes Control and Complications Trial (DCCT) (5) reported for the first time that 
long-term, intensified conventional insulin treatment could delay the development 
and the progression of microvascular lesions in Type 1 diabetes mellitus. These 
fundamental observations resulted in the development of many insulin analogues and 
also of sophisticated devices for continuous, subcutaneous insulin administration. The 
goal of these analogues and devices was to mimic the physiological blood insulin 
profile and thus to produce near-normal glycaemia in patients. Furthermore, the 
Swedish National Guidelines for diabetes care were formulated, as in other countries, 
with the aim of achieving good quality of life for patients with diabetes. The 
Guidelines also included recommendations for the allocation of resources in an 
equitable way. The Guidelines have been regularly updated since 1993. The most 
recent Guidelines were published in 2010 (18). 
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The National Guidelines recommend that patients with Type 1 diabetes be offered the 
following: 
 
 advice for a healthy life style related to diet, physical exercise and non-
smoking, 
 assistance in lowering blood pressure and reaching lipid levels that may 
reduce the risk of cardiovascular disease, 
 intensive treatment in order to achieve the best possible blood sugar 
levels, 
 NPH insulin and insulin analogues, and insulin pumps if blood sugar 
levels are volatile, 
 group education that takes cultural background into consideration, 
 periodic check-ups for foot problems with foot treatment if the risk for 
foot ulcers is high, and 
 physiotherapeutic treatment for shoulder pain. 
 
In addition to advances in medical treatment, diabetes management has made 
advances in the changes in the level of care and in the recognition of the benefits of 
patient involvement. The medical advances include multiple daily injection regimens, 
the use of insulin pumps, and new insulin analogues (17, 19). In order to use 
resources more effectively, there has been a shift from hospital inpatient care to 
daycare, from visits to specialists in hospitals to visits to family doctors, as well as 
from visits to physicians to visits to diabetes specialists. Another major advance is the 
increased recognition of the importance of the role of the patient in disease self-
management (18).  
 
The National Board of Health and Welfare evaluated Swedish diabetes care in 2011. 
The evaluation revealed positive results and improved advances, in terms of both 
process measures and outcome measures. However, the evaluation also stated that there 
was room for improvement, especially concerning the achievement of HbA1c levels, in 
particular for individuals with Type 2 diabetes. Another concern was the lack of 
culturally adapted patient education. The main data source was the National Diabetes 
Register (NDR), in which the quality of diabetes care is measured by clinical 
parameters. NDR, which  covers approximately 90% of the diabetic population (20), 
facilitates monitoring individual patient development of certain risk factors. NDR also 
allows healthcare facilities to compare their results from year to year and to benchmark 
their results against national averages.  
 
 
2.2.1 Diabetes care in Sweden 
In Sweden, the responsibility for financing and organising health services lies with 
the 20 county councils, and in some cases, with the municipalities. The Health and 
Medical Service Act regulates the responsibilities of county councils and 
municipalities, and gives local governments some freedom. Public providers provide 
the majority of healthcare services to the public, but the share of such services 
provided by publicly funded private producers has increased, especially in primary 
care. In 2011, visits to private physicians in primary care accounted for 40% of all 
medical visits and visits to private specialists for 24% (21). In this taxpayer-funded, 
decentralised system, the national government contributes to information distribution, 
for example, by National Guidelines.  
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In Sweden, the number of visits to physicians in primary care has increased by 12% 
from 2007 to 2011. The number of hospital visits has also increased annually whereas 
the total number of in-hospital patient days has decreased. The average length of 
hospital stay in 2007 was 5.8 days; in 2011 it was 5.3 days. Because fewer patients 
require inpatient care, they can be treated in daycare (e.g., day surgery). On average 
there were 0.41 day-surgery visits for each inpatient visit in 2010. In 2006, there were 
0.36 such day-surgery visits (21). 
 
In order for diabetes care to function effectively, well-functioning care routines and 
cooperation (between diabetes patients and the diabetes team) are needed (3). Type 1 
diabetes patients are mostly treated at hospital diabetes clinics whereas most Type 2 
diabetes patients are treated at primary care units (unless the cases are complicated) 
(22). Multiprofessional teams are responsible for most diabetes care in Sweden. 
These teams have physicians with special responsibility for patients with diabetes, 
and diabetes nurses as key members, but may also include dieticians, podiatricians, 
counsellors and physiotherapists. Although almost all hospital diabetes clinics use 
such multiprofessional teams, only 30% of the primary care units have diabetes 
teams. However, 90% of the primary care units reported they have a diabetes-
educated nurse (22). 
 
Of the diabetes clinics, 70% offer group training for people with Type 1 diabetes and 
40% offer group training for people with Type 2 diabetes. Only 3% of the clinics 
offer training that takes different patient cultural backgrounds into consideration (22). 
 
Patient fees cover only a small percentage of the healthcare costs in Sweden. The 
patient fee for a hospital stay is 80 Swedish crowns per day for the first ten days and 
thereafter 60 crowns/day. Fees for primary care, which vary depending on the county 
councils, range from 100 to 200 crowns per visit. The fee for a specialist visit is an 
additional 350 crowns. For patients with high utilisation of health care or high costs 
for prescription medication, there is an annual high-cost ceiling of 900 to 1,100 
crowns for medical consultations and 2,200 crowns for prescription medications. 
 
 
2.2.2 Healthcare reforms in Sweden 1983-2008 
There have been several important reforms of the Swedish healthcare system since 
the early 1990s when Jonsson (23) conducted her study on diabetes care. While most 
of these reforms were general reforms that did not necessarily affect diabetes care, 
some reforms were more likely to affect the care of people with diabetes. 
 
With the Patient Choice Reform, initiated in 1991, people were given the right to 
choose their healthcare providers (24). This reform was expanded in 2001 to include 
hospital outpatient care. In 1997, the Medical Products Reform was launched which 
redirected responsibility for medications from the national government to the county 
councils. The main justification for this reform was the government’s need to manage 
the continual increase in the costs of medications in a more rational and cost effective 
way. Each county council now has a medication committee that is responsible for a 
safe, rational and cost-effective pharmacotherapy. 
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For years, the Swedish public has complained about long waiting times for health 
care. Several reforms have tried to tackle this problem. In 2000, the National Action 
Plan for Health Care was introduced (24). Its aim was to strengthen the primary care 
provided by the county councils and the municipalities in order to, among other 
things, improve care processes and increase access to care. The concern was that 
problems with access to elective care could create a serious credibility problem for 
the entire Swedish healthcare system. In 2002, the national government set aside 1.25 
billion crowns to be used to create a sustainable improvement in healthcare access 
(24). In 2008, another 1 billion crowns, were set aside to strengthen healthcare access, 
and in 2013, yet another 1 billion crowns were set aside (25). In 2005, the national 
government introduced a healthcare guarantee that states that patients are entitled to 
receive an appointment at a community healthcare centre within 8 days of initial 
contact, an appointment with a specialist within 90 days, and treatment within 90 
days (26).  
 
 
2.3 DIABETES CARE FROM A HEALTH SERVICES RESEARCH 
PERSPECTIVE 
The theoretical perspective of this thesis comes from health services research (HSR), 
which is applied research aimed at improving the quality, organisation and 
management of health services (27, 28). HSR can be defined as the examination of 
”how people get access to health care, how much care costs, and what happens to 
patients as a result of this care” (29). It builds on scientific enquiry involving different 
disciplines including economics, epidemiology, public health, medicine, operations 
management and psychology. The underlying aim of HSR is to conduct research that 
can be applied by physicians, nurses, health managers and administrators, and other 
decision-makers in the healthcare sector.  
 
HSR overlaps with health policy and systems research (HPSR) (30) in which health 
systems are often described as six building blocks: health services; health workforce, 
health information; health financing; medical products and technologies; and leadership 
and governance (31). These blocks have their own dynamic response to their 
fluctuating environment. However, while HSR may focus on services and programmes 
for particular health conditions, HPSR has a broader perspective that considers the 
health system and policy context (30).  
 
HSR focuses on the input, process and outcome of health care with the aim of 
achieving an equitable healthcare system, or satisfactory quality, at an affordable price 
(27, 28, 32). This perspective implies that the focus of such research is the interaction 
between people with diabetes and the healthcare system, although it is recognised that 
individuals with diabetes and their families play a key role in managing the disease. 
Good health services are defined as services that deliver “effective, safe and quality 
personal and non-personal health interventions to people in a timely and geographically 
appropriate manner, and with a minimum waste of resources” (33), p. 3). In recent 
decades, certain factors have been identified that could affect the input of health care 
such as new medications, new forms of treatment, staff changes (e.g., working in 
diabetes teams), and more frequent use of diabetes nurses. In terms of process in health 
care, there have been changes in care levels with a shift towards outpatient care and 
primary care. There have also been changes in the staff-patient interaction where 
patients, to a larger extent, are more involved in their own care. Data on the process of 
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health care are important for evaluating if health service resources are used efficiently 
(32). Possible measures could be levels of use by different population groups as well as 
costs in relation to healthcare utilisation and medical treatment. Health outcomes are the 
effects of health services on patients’ health. Appropriate outcome measures to study 
changes in input and process could be patients’ perceptions of outcome in relation to 
their HRQoL and their satisfaction with the outcome and the mode (process) of 
delivering that care (28). As diabetes care covers various parts of the healthcare system, 
and collaboration between the different parts are vital for supporting individuals with 
diabetes, repeated measurement and analysis of healthcare utilisation patterns, costs and 
HRQoL in a population with a chronic disease may indicate problems in the health 
system as a whole. 
 
In studying the utilisation and costs of health services, it is of great importance to 
balance need (what people benefit from), demand (what people ask for), and supply 
(what is provided). The need for health is related to the overall aim of a healthier 
population (27). However, need is a relative concept and is very much dependent on 
socio-economic and cultural factors (28). 
 
In studies on utilisation and costs of health services it is also of importance to apply a 
longitudinal perspective. One possibility is then to follow cohorts of individuals over 
time. This is, however, a quite expensive and difficult approach. A more feasible 
alternative is to use already registered cohorts of individuals with different 
characteristics as well as existing data from such registers, and adapt these to the 
research questions at hand. In the context of this thesis research it was possible to use a 
selection of diabetes incidence cohorts with various disease durations, and design a 
study, which included cross-sectional analyses and comparisons. The findings and their 
interpretation could through such an approach be linked to disease duration although 
the data collected were not directly related to a longitudinal follow-up of the cohorts.  
 
 
2.3.1 Healthcare utilisation 
The excess use of healthcare services by patients with diabetes is partly the reason 
that diabetes creates a substantial economic burden on society (34, 35). Changes in 
healthcare utilisation patterns and excess healthcare utilisation are partly a reflection 
of the effectiveness and efficiency of the healthcare system in treating patients with 
diabetes (36, 37). Previous studies in other contexts indicate that healthcare utilisation 
related to diabetes changes over time as a function of disease duration (38-42). The 
effects of disease duration on excess healthcare use have also been shown in Sweden 
(34), but not the changes in the utilisation of healthcare services over time. 
 
Parslow et al. (43) found that there are gender differences in the use of healthcare 
services and that some differences can be explained by women’s use of reproductive 
health services. However, even when women’s visits to gynaecology and obstetrics 
departments are omitted, their use of healthcare services is still higher than men’s. 
Other factors that influence the level of healthcare utilisation are lower self-rated 
health (SRH), lower incomes and lower education levels. In addition, people with 
diabetes may have depression symptoms that may account for higher healthcare 
utilisation (44). 
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2.3.2 Excess costs 
In 2007, the International Diabetes Federation (IDF) estimated the direct costs of 
diabetes to the healthcare sector in various countries. The estimation, which was 
based on a model that assumed the prevalence of diabetes in each country would be 
6%, concluded that the cost of care for a person with diabetes is 2.5 times greater than 
that of a person without diabetes (35). The IDFs new estimates of healthcare spending 
due to diabetes show that on average $5,063 per person is spent in high-income 
countries compared to $271 in low- and middle-income countries. The estimate for 
Sweden was $5,440 per person (2). 
 
Estimating costs can be done using either a top-down or a bottom-up strategy (45). A 
top-down strategy uses published data based on aggregate figures on consumption 
related to diagnosis, e.g., diabetes. The disadvantage of this approach is that it could 
miss costs of diabetes-related complications, e.g., cardiovascular disease, unless 
diabetes is registered as the main diagnosis. A bottom-up strategy, which involves 
cost estimates derived from an investigation of a sample of people with diabetes, 
permits a more comprehensive inventory of the utilisation and costs of diabetes care 
than is possible using only data from databases in the healthcare system. In a bottom-
up strategy, it is also easier to analyse the relationship between different background 
characteristics of the people with diabetes and the costs of care. 
 
Cost analyses should preferably be based on opportunity costs (i.e., the value of the 
forgone benefits because the resource is not available for its best alternative use), the 
pragmatic approach to costing is to take existing market prices unless there is some 
particular reason to do otherwise (45), p. 57). Unfortunately, it is often difficult to 
conduct costing studies if hospital costs are not very detailed. Because of the 
unavailability of data, it is common that assumptions about costs are made, for 
example, by using general per diem or average hospital costs (28, 45). 
 
Several studies have shown that the healthcare costs related to diabetes are a substantial 
burden on society (34, 37, 46-62). The reason is partly due to the high prevalence and 
increasing incidence of Type 2 diabetes. Healthcare costs have also increased by 
approximately 20% since 2002 because of the ageing population and because of the 
development of new and more expensive treatments (21). In Sweden, healthcare costs 
are approximately 14% of GDP (21). Of these costs, 6-7% are calculated as attributable 
to diabetes care (54, 63).  
 
The excess costs for diabetes vary considerably with patient age (54). The 
diabetes/non-diabetes cost ratio was higher among children (7.7) than among people 
over 75 years of age (1.4). Costs have also been found to increase with diabetes 
duration (63). The direct costs for diabetes in Sweden have been estimated at around 
40% of total costs for diabetes, and the indirect costs (i.e., production losses due to 
morbidity and premature death) at around 60% (63, 64). Henriksson et al. (63) found 
that the direct costs were almost 50% higher for patients with longer diabetes duration 
than ten years compared with patients with a diabetes duration of less than five years. 
In two Swedish population-based incidence cohorts (from 1983 and 1992; diagnosed at 
the age of 15-34 years), were investigated one and eight years after diagnosis. The 
estimated costs for medical care after one year was 5.6 times higher for patients with 
diabetes than for the age- and sex matched control group, whereas the corresponding 
figure after eight years was 3.8 (34). 
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Diabetes costs can be divided into two categories: costs for the prevention and 
treatment of diabetes and costs for diabetes-related complications (65). The largest 
impact on costs of diabetes care results from diabetes-related complications rather than 
direct costs for the actual treatment of diabetes (52, 63, 66-71). Studies conducted in 
clinical settings have confirmed that intensive management of diabetes can prevent, or 
at least postpone, the occurrence of long-term complications (5, 17, 72) and can reduce 
the considerable social and economic consequences of the disease to the individual and 
to society (23, 73, 74). As a consequence, when costs are shifted to the early years 
following diabetes diagnosis, the total overall costs of the disease may decrease and the 
cost-effectiveness of diabetes care may improve. On the other hand, intensive treatment 
regimens may negatively influence HRQoL in early diabetes care even though the 
reverse (i.e., improved HRQoL) may be the eventual outcome.  
 
As the treatment of diabetes has changed considerably in the three last decades, it is 
likely that the costs for diabetes care have risen. Follow-up or repeat studies are 
therefore important in order to compare excess costs over time and to obtain new cost 
estimates that reflect current treatment practices. This research was conducted 16 
years after Jonsson’s (34) study of the 1983 and 1992 cohorts with a disease duration 
of 8 years and 1 year, respectively. Repeat investigations of these cohorts, now with 
disease durations of 24 and 15 years, respectively, enabled the analysis of healthcare 
utilisation and the use of medications over a longer time period. Furthermore, 
inclusion of two new cohorts from 1999 and 2008, with disease durations of 8 years 
and 1 year, respectively, enabled direct comparisons with the earlier study. 
 
 
2.3.3 Health-related quality of life 
Because diabetes is associated with both a risk for acute and chronic complications, it is 
likely to affect HRQoL. HRQoL is a subjective assessment of health status that 
includes aspects such as general health, physical, emotional, cognitive, and role 
functioning, as well as social well-being (75).  
 
For individuals with diabetes, HRQoL can be measured with a diabetes-specific 
instrument that may detect subtle disease and treatment-related effects (76-79), or with 
generic instruments that enable comparisons to the general population or to other 
diseases (79-82). The choice of type of instrument depends on the research question 
and which decisions one wants to make based on the results (83). In order to compare 
the difference between individuals with varying diabetes duration, and the difference 
between individuals with diabetes and the general population, a generic instrument is 
the most appropriate choice. The literature supports the use of generic HRQoL 
instruments for measuring health status in individuals with diabetes. Examples of such 
instruments are the Short Form 36 (SF-36), the Health Utility Index (HUI), and the EQ-
5D (76, 84, 85). The EQ-5D, which is a short instrument that can be included in any 
questionnaire, has been used in the general population as well as with a wide range of 
health conditions and treatments (86). 
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2.3.4 Equity perspective 
Equity in health implies that resources will be distributed and processes will be 
designed in ways that are fair and just, while recognising that different groups in a 
population have different needs and power (87, 88). One main goal of Swedish health 
care is to provide equitable access to high quality care regardless of age, sex, 
geographic area, social status, or ethnic background (89). However, despite efforts to 
reduce inequities in health and health care in recent decades, there are few indications 
that gender and socio-economic inequities have diminished in Sweden (90).  
 
Gender-specific analyses from the study in the early 1990s showed that, 8 years after 
diagnosis, the excess costs were higher for women than men, mainly due to women’s 
more frequent use of hospital outpatient care and more intensive glucose monitoring 
(36). SRH was poorer among individuals with diabetes than in population controls 
both 1 year and 8 years after diagnosis (91). This difference was found in men and 
women and in the socio-demographic subgroups studied except among individuals 
from upper social class backgrounds or with academic educations. These findings 
suggested the interaction between (female) gender and (low) social class are 
predictors of poor SRH. Gender and socio-demographic factors were more closely 
associated with SRH 8 years after diagnosis than 1 year after diagnosis, suggesting 
early socio-demographic stratification in the health of the diabetic population. 
 
 
2.4 JUSTIFICATIONS 
The prevalence of diabetes mellitus in Sweden is increasing (as well as in other 
countries) and therefore creates a substantial economic burden for society (52, 92). 
Because the patterns of healthcare utilisation are closely related to the direct costs of 
diabetes (36), the value of this research is its examination of the changes in healthcare 
utilisation patterns that may reflect the effectiveness and efficiency of the healthcare 
system. The trade-offs between early diabetes control and the occurrence and severity 
of long-term complications can be addressed by comparing diabetes patients’ 
healthcare utilisation and HRQoL with control individuals’ healthcare utilisation and 
HRQoL. In this thesis, it was possible to apply a longitudinal approach using yearly 
cohorts from the DISS registration of all incident cases of diabetes in the 15 to 34 years 
age group. 
 
The four cohorts of individuals with diabetes selected for this thesis represent the 
development of diabetes in different phases and its associations with healthcare 
utilisation, costs and HRQoL 1, 8, 15 or 24 years after diagnosis. Two cohorts, 1983 
and 1992, were studied previously at 8 years and 1 year after diagnosis, respectively 
(23). This research was conducted 16 years after Jonsson’s study of the 1983 and 1992 
cohorts. Follow-up of these cohorts, now with disease durations of 24 and 15 years, 
respectively, will enable the analysis of healthcare utilisation and the use of 
medications over a longer time period. This longitudinal approach to the examination 
of patterns and costs may indicate if changes in diabetes treatment and management 
have had any effect. Furthermore, two new cohorts from 1999 and 2008 were included, 
also with disease durations of 8 years and 1 year, respectively, which will enable direct 
comparisons with the previous study. It was hypothesised that the direct costs of 
diabetes during the first year after diagnosis may have increased since the early 1990s 
due to more counselling and treatment efforts, while the costs 8 years after diagnosis 
may not have changed significantly. Furthermore, due to the intensive treatment of 
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diabetes in the early stages, the HRQoL for the patient with diabetes was likely to be 
negatively affected whereas HRQoL was expected to improve in the stable stages of the 
disease. However, with longer disease durations and the possibility of potential 
diabetes-related complications, a gradual decrease in HRQoL beyond that of the 
general population was expected. As there are few indications of diminishing gender 
and socio-economic gradients in health and health care (90), it was expected that there 
would be no change in the previously observed differences.  
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3 AIMS AND OBJECTIVES 
 
The main aims of this thesis were to analyse how healthcare utilisation, costs and 
health-related quality of life differ for individuals with diabetes compared to control 
individuals from the general population and to analyse how these differences are 
associated with disease duration and changes in the healthcare over time. A further 
aim was to explore diabetes care from an equity perspective. 
 
The specific objectives were: 
 
a) To describe healthcare utilisation patterns in young and middle-aged patients 1 year 
and 8 years after diagnosis and to compare with the general population at two time 
points 16 years apart, in the early 1990s and in the late 2000s. 
b) To compare the estimated annual excess costs for the treatment and management of 
diabetes in four cohorts (1, 8, 15 and 24 years after diagnosis), and with estimates of 
excess costs in two cohorts from the early 1990s (1 year and 8 years after diagnosis). 
c) To describe and analyse HRQoL in individuals with onset of diabetes between 15 
and 34 years of age and with a disease duration of 1, 8, 15 and 24 years, and to 
compare these individuals with the general population. 
d) To explore the role that gender and socio-economic factors play in healthcare 
utilisation, dissatisfaction with services and SRH in Sweden for individuals with 
diabetes compared with the general population. 
 
In this thesis, time after diagnosis has been used as a proxy for disease duration. 
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4 METHODS 
 
As was described earlier, health services research focuses on the input, process and 
outcome of healthcare services. This thesis focuses on the following outcome 
measures: healthcare utilisation, costs of medical care, and HRQoL. These measures 
may indicate how the changes in the processes of the healthcare system are associated 
with providing equitable health care. It is a cross-sectional examination of four diabetes 
cohorts with elements of case-control analyses in the four studies. 
 
 
4.1 STUDY POPULATION 
In 1983, the Diabetes Incidence Study in Sweden (DISS) was initiated with the aim of 
identifying important factors in the development of diabetes and its complications (93). 
DISS registers all incident cases of diabetes mellitus in the age group 15 to 34 years 
based on reports from all departments of medicine and endocrinology and all primary 
health care units in Sweden. Each year, approximately 400 cases are registered. A 
standardised form is used to record basic information about patients at the time of 
diagnosis (personal identification number-PIN, name and address, date and place of 
diagnosis, basis for diagnosis, height and weight). In addition, the physician’s clinical 
classification of the type of diabetes is reported. Since 1998, blood samples for 
determination of islet cell antibodies have been delivered to a central laboratory in 
order to improve the classification of diabetes. The ascertainment level has been 
estimated at 80% (94). A 20-year follow-up by DISS found that 74% of the individuals 
in the register were diagnosed with Type 1 diabetes, 15% had Type 2 diabetes, and 
10% were difficult to classify at diagnosis (93, 95).   
 
The study population for this thesis consists of cases of diabetes diagnosed in the years 
1983, 1992, 1999 and 2008. In this follow-up, conducted about 25 years after DISS was 
initiated, the patients in the four cohorts had had diabetes for approximately 24 years, 
15 years, 8 years or 1 year, respectively. The assumption behind the selection of these 
four cohorts was that, over this span of years, the patients would have experienced both 
short- and long-term complications. In addition, these complications would have 
affected their healthcare use and their HRQoL. One data file for each year cohort in 
DISS containing PINs was sent to Statistics Sweden for identification of control 
individuals from the general population register. For each individual in DISS, two 
control individuals (matched by age, gender and county of residence) were selected at 
the time of the follow-up. In the general population register, demographic 
characteristics of Sweden’s population are reported by age, sex, marital status, 
citizenship, country of birth, migration, birth and death (96). Two cohorts, 1983 and 
1992, were followed-up in the early 1990s using the same matching procedure for 
control individuals. 
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4.2 DATA COLLECTION 
 
4.2.1 Procedure 
A survey questionnaire and explanatory letter were mailed by post to the 1983, 1992 
and 1999 cohorts and matching control groups in January 2008, asking for 
information about the previous year (i.e., approximately 24, 15 or 8 years after the 
diabetes diagnosis; see Appendix 1). During 2009, the same survey questionnaire was 
mailed by post quarterly to the 2008 cohort and to another set of matching control 
group (i.e., 1 year after the individual date of diagnosis of each patient with diabetes). 
Response envelopes were enclosed with the questionnaire so that the responders 
could answer by post. Responders could not answer via the Web or by email. 
 
Two weeks after the mailing of the questionnaire, a first reminder was sent to all 
cohorts. A second reminder was sent to all cohorts, two weeks later, with another copy 
of the questionnaire. Eight weeks later a third reminder was sent to the 1983, 1992 and 
1999 cohorts. This third reminder was not sent to the 2008 cohort because the third 
reminder sent to the other cohorts had not added much to the final response rates. The 
questionnaire was in Swedish. However, recipients could request an English version of 
the questionnaire by contacting the thesis author by mail or telephone. 
 
Statistics Sweden, which administered the questionnaire for the 1983, 1992 and 1999 
cohorts, was responsible for both the distribution and the optical reading of the 
questionnaires. Statistics Sweden also sent the questionnaire to the 2008 cohort but the 
thesis author registered all responses and managed the data. See Figure 1 for a 
flowchart of the data related to the mailed questionnaires. 
 
 
 
FIGURE 1. Data collection: Numbers of individuals with diabetes (D) and control individuals (C), 
*a third reminder was not sent to the 2008 cohort. 
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4.2.2 Questionnaire 
The questionnaire had 27 numbered questions. With the 47 sub-questions, the 
questionnaire had 74 questions in total. Individuals with diabetes were asked to respond 
to an additional 12 diabetes-related questions with 11 sub-questions. Therefore, these 
individuals responded to 97 questions in total.  
 
The questionnaire addressed the following aspects of health care: HRQoL; healthcare 
utilisation; prescription and non-prescription medication use; short- and long-term sick 
leave; dissatisfaction with health care; and socio-demographic issues. The 
questionnaire, which also had diabetes-related questions about the use of insulin, 
devices and test materials, was an updated version of the questionnaire used in earlier 
studies from 1991 and 1993 by Pia Maria Jonsson (23). For the research for this thesis, 
minor changes were made to the previous questionnaire. For example a few questions 
were deleted as no longer relevant. The EQ-5D questionnaire (explained next) was 
added in order to make comparisons with population studies and studies using EQ-5D 
in other diabetes populations.  
 
Data on HRQoL were collected using the SWED-QUAL instrument, which is a 
modified translation of SF-36 that covers physical functioning, role functioning, 
emotional functioning, well-being, pain, sleep, family functioning and general health 
perceptions (97). In order to compare different generic methods for the measurement of 
HRQoL in men and women with diabetes, the questionnaire also included the EQ-5D 
instrument (86). The EQ-5D, which is less extensive than the SWED-QUAL, provides 
access to comparison materials both in disease populations (85, 98-104) and in the 
Swedish general population (81, 105).  
 
Data on healthcare use patterns were gathered from responses to structured questions 
about the numbers of contacts with different healthcare areas. Some questions 
requested the number of contacts for hospital outpatient care, hospital emergency room 
treatment, and clinic visits in the most recent three months. Other questions requested 
information on the number of days for inpatient care and daycare in the last year. 
Daycare was defined as visits to hospitals for participation in education or training 
programmes, for operations, or for other procedures where observation, although not 
overnight stay, is required. Inpatient care covered hospital admissions as well as total 
length of stay at different clinics. The questionnaire also requested information on the 
number of visits to community healthcare centres or private practitioners and the 
number of house calls by nurses or physicians from community healthcare centres in 
the most recent three months.  
 
The Swedish Surveys of Living Conditions conducted by Statistics Sweden (106) 
guided the construction of the questionnaire (e.g., for wording and recall periods). 
 
 
4.2.3 Additional data sources 
Informed consent was requested from all questionnaire responders in order to complete 
the data set with socio-economic variables available in the Longitudinal integration 
database for health insurance and labour market studies (LISA by Swedish acronym) 
hosted by Statistics Sweden (107). Variables included were education level, gainful 
employment, income level, sick leave days and early retirement as registered in the 
database 2006 (education level included Spring term 2007).  
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Data for calculating costs for inpatient and outpatient care were obtained from the 
Swedish Association of Local Authorities and Regions (108) as well as from various 
counties’ price lists for care for patients from other counties (109-112). Costs for 
materials, test devices and insulin and other glucose-lowering medications were 
obtained from the Dental and Pharmaceutical Benefits Agency (113).  
 
 
4.2.4 Responders and non-responders 
The overall response rate for all four cohorts was 54% for individuals with diabetes and 
51% for control individuals. The response rate varied between the different cohorts (the 
rate was especially low in the 2008 cohort) and was generally lower compared to the 
previous study conducted in the early 1990s. Low response rates are an increasing 
problem in surveys and have also been experienced by, for example, Statistics Sweden 
(114, 115). Table 1 shows the response rates for the different cohorts, both for this 
study and for the previous study. 
 
TABLE 1. Response rates for the different cohorts 
 
Incidence cohorts 1983 1992 1999 2008 
 Case Control Case Control Case Control Case Control 
 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Follow-up year 1991 1993         
Disease duration 8 years 1 year         
Total sample 442  865  322 658    
Responses 317 (72) 586 (68) 237 (74) 443 (67)    
Follow-up year 2007 2007 2007 2009 
Disease duration 24 years 15 years 8 years 1 year 
Total sample 422  841  418 828 409 815 340  681  
Responses 276 (65) 530 (63) 228 (55) 434 (52) 217 (53) 396 (48) 143 (42) 256 (38) 
 
 
As the response rates were low, we asked Statistics Sweden to contact a random sample 
of the non-responders by telephone in 2008. In total, 300 individuals were contacted, of 
whom 150 were reached. Most of the non-responders remembered having received the 
questionnaire (89% of the individuals with diabetes and 84% of the control 
individuals). The non-responders gave several reasons for not responding. The most 
common reasons were lack of time (44%; 36%) and just not wanting to respond (27%; 
23%). Another reason was the length of the questionnaire (17%; 16%). 
 
They were also asked the SRH question about their health at that moment on a five-
point scale (“In general, would you say your health is: very good; fairly good; fair; 
rather poor; very poor?”). Among the individuals with diabetes, 32% rated their health 
as less than good compared to 16% among the control individuals. 
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4.3 OVERVIEW OF THE FOUR STUDIES 
The four research studies of this thesis use the data collected in the postal questionnaire. 
Figure 2 shows the cohorts used in each of the studies. In addition, Figure 2 shows that, 
for two studies, comparisons were made with studies from the early 1990s. 
 
FIGURE 2. Overview of the studies 
 
 
4.4 OUTCOME MEASURES 
The main outcome measures for this thesis are healthcare utilisation in hospital and in 
primary care, costs for healthcare utilisation (and for the individuals with diabetes, 
costs of treatment and monitoring), and HRQoL as measured by EQ-5D. In addition, 
equity in terms of how socio-demographic factors influence the first three outcomes 
was explored. 
 
 
4.4.1 Healthcare utilisation (Study I) 
In this case-control study, the effect of diabetes on healthcare utilisation was analysed 
using retrospective data from the questionnaire in order to compare utilisation patterns 
1 year and 8 years after diagnosis. Comparable data from the early 1990s was used to 
describe changes in the 16-year period.  
 
Questions about utilisation addressed both outpatient care and inpatient care (Table 2). 
The questions asked for data on the number of visits to various hospital outpatient 
clinics and hospital emergency rooms, visits to community health centres and private 
practitioners, house calls from community healthcare centre personnel, and visits to 
occupational healthcare offices. The recall period was three months. Inpatient care and 
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daycare at hospital clinics were surveyed for the most recent year, with questions on the 
number of stays and days at inpatient clinics and the number of days at daycare clinics. 
 
TABLE 2. Specification of which clinics were covered in the questionnaire 
 
 Hospital outpatient clinics  
(recall period 3 months)
Hospital inpatient clinics 
(recall period 1 year) 
Daycare  
(recall period 1 year) 
Internal medicine/endocrinology X X X 
Surgery/orthopaedics/urology X X X 
Gynecology X X  
Ophthalmology X X  
Ear, nose and throat X X  
Psychiatry X X  
Diabetes X  X 
Other X  X 
Emergency department X   
 
 
4.4.2 Costs of medical care (Study II) 
Estimated healthcare costs were divided among the following categories: hospital 
inpatient care; daycare; hospital outpatient care; non-hospital outpatient care; and 
glucose-lowering treatment and monitoring. Costs were estimated using the collected 
data on resource consumption (quantity), which was multiplied by a unit cost (price). 
The resources consumed were extracted from the questionnaire described above; the 
reported data were extrapolated to provide an estimate of the annual resource 
consumption. For example, the number of outpatient visits in the three-month period 
was annualised (3-month visits x 4) as yearly visits. Similarly, the use of medications 
and test devices was annualised (two-weeks use x 26) as the yearly use.  
 
The excess costs of medical care for the diabetes patients were calculated as the 
healthcare cost difference between the diabetes cohorts and the control groups. The 
excess costs are presented as cost ratios for the diabetes cohorts and the control groups 
(diabetes/non-diabetes ratio) in order to facilitate comparisons with other studies. 
 
Unit costs for different types of inpatient and outpatient care were collected from data 
compiled by the Swedish Association for Local Authorities and Regions as well as 
from price lists used for care of out-of-county patients (108). An average cost for 
inpatient care, daycare, outpatient hospital care, and non-hospital outpatient care was 
calculated as the mean of the costs for the different sources. Pharmaceutical prices 
published by the Dental and Pharmaceutical Benefits Agency were used to calculate 
costs for insulin, oral hypoglycaemic agents and other glucose-lowering medications 
and devices (113). The estimated costs were calculated by multiplying the average 
costs for insulin type with the average use of insulin per day. The costs are expressed in 
Swedish crowns (SEK) at 2009 prices (mean exchange rates for 2009: 1 USD=7.65 
SEK and 1 EUR=10.62 SEK). The results from the previous studies were inflated from 
1997 to 2009 year prices using the Swedish Consumer Price Index for Sweden. 
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4.4.3 Health-related quality of life (Study III) 
EQ-5D is a standardised instrument used to measure health outcomes for a wide range 
of health conditions and treatments for patients as well as for the general population 
(81, 86). With the EQ-5D measure, respondents classify their health status in five 
dimensions (mobility; self-care; usual activities; pain/discomfort; anxiety/depression), 
and at three levels of severity (no, moderate or severe problems). In this classification, 
243 possible unique health states can also be converted into a single index value (EQ-
5Dindex) for health status (1=full health; 0=dead). The index value is assigned by 
adopting the most commonly used value set, the York MVH A1 value set, which 
derives from valuations of health states representing the average preference of the 
general UK population (116). The EQ VAS score was recorded on a scale from 0 
(worst imaginable health state) to 100 (best imaginable health state), where respondents 
were asked to identify their present health state. 
 
 
4.4.4 Equity in healthcare (Study IV) 
Six variables from the questionnaire were used to evaluate the effect of diabetes: 
case/control, sex, age, marital status, education level and income (sum of income from 
work, studies, military duty and parental leave). The dependent variables were coded so 
that the category of interest was use of healthcare, dissatisfaction with care received, or 
reporting less than good SRH.  
 
Global SRH has been widely used as a reliable indicator of an individual’s health. 
Therefore, SRH was selected as an indicator of the respondent’s health status at the 
time of the survey. The respondents were also asked if they had had any problems 
receiving the care they needed. If the respondents answered affirmatively, they were 
asked to describe these problems. 
 
 
4.5 DATA ANALYSIS 
Data were analysed using Statistical Package for Social Sciences (SPSS versions 16-20; 
IBM Corporation, New York, USA). Table 3 presents an overview of which statistical 
tests were used to analyse the data in the four studies. Level of significance was 
determined at P < 0.05. 
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TABLE 3. Overview of statistical tests in the four studies. 
 
Study Variables1 Pearson’s χ2-test 
or Fisher’s exact 
test 
Independent 
samples t-test 
Regression One-way 
ANOVA 
I DV: visits to 
different types of 
healthcare 
facilities 
IV: case/control, 
sex 
Socio-
demographic 
characteristics 
Differences in 
utilisation patterns 
among patients 
with diabetes 
between the 
respective 1- and 
8-year cohorts. 
 Logistic regression. 
Case-control 
comparison using 
odds ratios and 
95% CI 
 
II Costs for 
healthcare 
utilisation, and 
monitoring and 
treatment of 
diabetes 
Socio-
demographic 
characteristics 
Differences in 
mean costs 
between 
patients with 
diabetes and 
control 
individuals 
 Differences in 
mean costs 
between 
patients with 
various 
diabetes 
duration. Post-
hoc tests: 
Bonferroni and 
Dunnett T3 
III DV: EQ-5Dindex 
and EQ VAS 
score 
IV: sex, diabetes 
diagnosis, 
disease duration, 
level of education 
and marital 
status 
Socio-
demographic 
characteristics 
Percentage of 
reported problems 
in the EQ-5D 
dimensions 
Differences in 
the mean EQ-
5Dindex and EQ 
VAS score 
between 
diabetes 
individuals with 
various disease 
duration. 
Multivariate linear 
regression. 
Identification of 
factors predicting 
variation in mean 
EQ-5Dindex and EQ 
VAS score 
Differences 
between 
diabetes 
individuals with 
different 
disease 
duration. Post-
hoc tests: 
Bonferroni and 
Dunnett T3 
tests 
IV DV: healthcare 
utilisation, 
dissatisfaction 
and SRH 
IV: case/control, 
sex, age, marital 
status, level of 
education and 
income 
Socio-
demographic 
characteristics 
 Univariate analysis 
to find IV of 
interest. Backward 
conditional (Wald) 
stepwise logistic 
regression to 
examine the 
strength, using 
unstandardised 
coefficients 
 
1DV=dependent variables, IV=independent variables 
 
 
4.5.1 Study I 
The five-category question concerning the level of education was dichotomized in the 
analysis into short education (secondary school or lower) and long education (college 
or university). Marital status was dichotomized into married or cohabiting, and single. 
Visits to clinics were dichotomized into no visits and one or more visits. 
 
The study analysed the impact of diabetes on healthcare utilisation. Patients with 
diabetes were compared with control individuals in a logistic regression analysis that 
calculated the odds ratios (ORs) and 95% confidence intervals (CIs). Pearson’s χ2-test 
was used to compare utilisation patterns between the respective 1- and 8-year cohorts 
of patients with diabetes.  
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4.5.2 Study II 
Pearson’s χ2-test, or where appropriate Fisher’s exact test, was used to test whether 
there was a difference in socio-demographic characteristics between patients with 
diabetes and control individuals in the various cohorts. Independent samples t-test was 
used to test whether there were differences in the mean healthcare costs between 
patients with diabetes and control individuals. Comparisons between patients with 
different diabetes duration were performed using one-way ANOVA. Post-hoc tests 
were performed with Bonferroni and Dunnett T3 tests. 
 
 
4.5.3 Study III 
The main outcome measures were self-reported health as expressed in the five EQ-5D 
dimensions, the EQ-5Dindex and the EQ VAS score. Pearson’s χ2-test or Fisher’s exact 
test was used to test whether there was a difference in socio-demographic 
characteristics for patients and control individuals in the various cohorts, and the 
percentage of reported problems in the EQ-5D dimensions. The categories moderate 
and severe problems were collapsed before testing, resulting in the following two 
categories: moderate or severe problems, and no problems. Independent samples t-test 
was used to test whether there were differences in the mean EQ-5Dindex and EQ VAS 
score between control individuals and the individuals with diabetes in the four cohorts 
(1, 8, 15 or 24 years after diagnosis). Comparisons between individuals with different 
diabetes duration were performed using one-way ANOVA. Post-hoc tests were 
performed with Bonferroni and Dunnett T3 tests. The same tests were used for the 
control individuals. 
 
A multivariate linear regression analysis was performed to identify variables that could 
predict the variation in the dependent variables mean EQ-5Dindex and EQ VAS score. 
The independent variables included were sex, diabetes diagnosis, disease duration, 
level of education, and marital status. Level of education was dichotomised into 
primary school or lower and secondary school or higher, and marital status was 
dichotomised into married or cohabiting, and not married or cohabiting.  
 
 
4.5.4 Study IV  
Variables were included in multivariate analysis based on significance in univariate 
analysis (p<0.10). Indicator coding was used to explore, for dichotomous independent 
variables, whether the effect of one of the independent variables on the chances of 
falling in the category of interest in the dependent variable is the same for each 
category of the other independent variable (117). 
 
Backward conditional (Wald) stepwise multiple regression was used to identify the 
significant predictors of each dependent variable. The probability for variable entry was 
set at p≤0.05 and that for exclusion at p≥0.10 to find the most parsimonious model. 
Backward conditional stepwise logistic regression is regarded as the most sensitive 
stepwise approach in exploratory research (117) and has been widely used in such 
research (see, for example: (118-121).  
 
Interaction variables were used to investigate any equity issues regarding individuals 
with diabetes’ experience of health care and health status. Wherever the case/control 
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variable was significant in univariate analysis, interaction variables were created with 
the significant equity independent variable to test whether equity issues operated the 
same for those with diabetes in comparison to control individuals.  In addition, for any 
dependent variable where both marital status and gender were significant in the 
univariate analysis, an interaction variable of marital status*gender was tested with that 
dependent variable to explore whether any equity issues related to gender were in fact 
more deeply layered due to different effects of gender for different marital statuses. 
 
 
4.6 ETHICAL CONSIDERATIONS 
Information about the research purpose, its design and the voluntary participation was 
explained in a letter included with the questionnaire. The 1983, 1992, and 1999 cohorts 
were asked to sign an informed consent giving us permission to collect socio-economic 
data from Statistics Sweden. The letter sent to the 2008 cohort informed them that by 
responding to the questionnaire they implicitly permitted collection from LISA. 
 
The risk of privacy invasion was considered small. The data requested for the limited 
period (in connection with preparing the linking between different registers) disclosed 
the PINs of the sampled study population. However, the PINs were not available to the 
researchers at the Medical Management Centre because the data manager for the DISS 
at Umeå University sent the distribution of data with PINs to Statistics Sweden. The 
files received from Statistics Sweden did not contain PINs. Moreover, the 
corresponding diabetes studies conducted in the 1990s, to our knowledge, did not result 
in any complications as far as personal integrity issues or other undesirable 
consequences. Because all results from the analyses are presented at large group levels, 
no individuals can be identified using background characteristics. 
 
The study was approved by the Regional Ethics Committee in Stockholm 
(2007/214/31). 
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5 FINDINGS 
 
5.1 CHARACTERISTICS OF THE STUDY POPULATION 
Socio-demographic characteristics of the study population are described in Table 4. 
Because of the matching procedure, there were few differences in the socio-
demographic characteristics between the individuals with diabetes and the control 
individuals. However, there were more men than women in the cohorts, which reflected 
the higher incidence of Type 1 diabetes among men in this age group in Sweden (95). 
Eight years after diagnosis, there was a lower proportion of married or cohabiting 
individuals among men with diabetes than among the corresponding control 
individuals. One year after diagnosis, the level of education was significantly lower 
among men with diabetes than among the corresponding control individuals. 
 
Ninety-nine per cent of the individuals with diabetes stated that they had a blood 
glucose meter at home, and 96% stated that they measured their blood sugar levels. The 
mean use of a control procedure was 17 times/week (SD 15.5), based on the most 
recent week’s usage (Table 5).  
 
In this study, 4.2% of the patients 1 year after diagnosis used an insulin pump. In the 
other three cohorts, about 14% used an insulin pump. In the early 1990s, none of the 
patients 1 year after diagnosis used an insulin pump, whereas 3.2% of the patients 8 
years after diagnosis did (23). 
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TABLE 4. Socio-demographic characteristics of the individuals with diabetes and of the control individuals by disease duration 
 
  Diabetes duration 
1 year 8 years 15 years 24 years 
2008 cohort 1999 cohort 1992 cohort 1983 cohort 
Case Control Case Control Case Control Case Control 
n=142 (%) n=255 (%) p1 n=217 (%) n=392 (%) p1 n=229 (%) n=433 (%) p1 n=274 (%) n=530 (%) p1 
Sex 
Men 89 (63) 150 (59) 0.45 120 (55) 216 (55) 0.96 134 (58) 253 (58) 0.98 158 (58) 324 (61) 0.34
Women 53 (37) 105 (41) 97 (45) 176 (45) 95 (42) 180 (42) 116 (42) 206 (39)
Mean age2 26 26 34 34 40 40 50 50
Marital status 
Married/cohabiting 57 (42) 132 (52) 0.06 148 (68) 305 (79) 0.005 167 (73) 323 (75) 0.57 205 (75) 401 (76) 0.72
Single/divorced 80 (58) 123 (48) 69 (32) 83 (21) 61 (27) 106 (25) 69 (25) 127 (24)
Highest level of education 
Primary school  13 (9.4) 11(4.3) 0.006 20 (9.2) 26 (6.7) 0.54 39 (17) 40 (9.3) 0.02 66 (24) 102 (19) 0.21
Secondary school 82 (59) 131 (51) 97 (45) 170 (44) 110 (48) 209 (49) 113 (42) 207 (41)
College 24 (17) 55 (22) 52 (24) 90 (23) 35 (15) 98 (23) 44 (16) 115 (22)
University degree 13 (9.4) 52 (20) 42 (19) 95 (24) 40 (18) 75 (17) 42 (16) 76 (14)
Other 7 (5.0) 6(2.4) 6 (2.8) 8 (2.1) 3 (1.3) 7 (1.6) 6 (2.2) 16 (3.0)
Employed 72 (52) 146 (58) 0.31 182 (84) 340 (87) 0.26 200 (88) 371 (86) 0.56 223 (83) 455 (87) 0.13
1Comparison between cases and controls. 
2Age at the end of the year the respondents received the questionnaire. 
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TABLE 5. Treatment and monitoring of blood glucose levels 
 
 Diabetes duration   
 1 year 8 years 15 years 24 years   
 2008 cohort 1999 cohort 1992 cohort 1983 cohort   
Case Case Case Case  
n=142 % n=217 % n=229 % n=274 % p1
Treatment  
Diet 5 3.5 5 2.3 2 0.9 3 1.1 0.19
Oral hypoglycemic agents 15 10.6 24 11.1 17 7.4 17 6.2 0.19
Insulin pen (prefilled) 43 30.3 85 39.2 100 43.7 116 42.3 0.06
Insulin pen (multiple use) 76 53.5 99 45.6 108 47.2 148 54.0 0.18
Syringes 13 9.2 17 7.8 13 5.7 17 6.2 0.55
Insulin pump 6 4.2 32 14.7 32 14.0 38 13.9 0.01
 
Monitoring 
Blood glucose levels at home 133 95.7 207 95.8 223 97.8 258 95.6 0.55
Number of weekly controls (mean, SD) 18 16.4 19 16.3 16 14.2 17 15.2
Measuring of ketones 0 0 22 10.3 25 11.3 34 12.9 <0.001
1Comparison between the different cohorts using Pearson chi-square. 
 
 
The most commonly used insulin types in the 1983, 1992 and 1999 cohorts were 
Humalog™, Novorapid™ and Lantus™.  In the 2008 cohort, Novorapid™, Lantus™ 
and Levemir™ were the most commonly used insulin types.  
 
 
5.2 HEALTHCARE UTILISATION PATTERNS 
 
5.2.1 Healthcare utilisation 1 and 8 years after diagnosis  
5.2.1.1 One year after diagnosis 
In the 1992 cohorts, 49% of patients with diabetes had received inpatient care at 
departments of internal medicine and endocrinology at least once (Table 6). This was 
significantly higher than the control individuals (0.5%). In the 2008 cohort the 
difference was no longer significant, mainly because at this point in time, only 4.2% of 
the patients with diabetes had visited these departments, compared with 1.2% of the 
control individuals. In both cohorts, 45%-46% of the patients with diabetes made at 
least one visit to daycare, which was three times as many as the control individuals. 
 
A significantly higher proportion of patients with diabetes made more visits to the 
hospital outpatient clinics than the control individuals, both for 1-2 visits, and 3 or more 
visits (1 year after diagnosis 74% vs. 18%; 8 years after diagnosis 72% vs. 19%). Even 
after excluding visits to diabetes clinics, the utilisation of hospital outpatient clinics was 
still significantly higher. Specifically, patients with diabetes made significantly more 
visits to ophthalmology clinics. 
 
Patients with diabetes in both the 1992 and 2008 cohorts visited nurses more often than 
the control individuals: 11% and 16% of patients with diabetes compared with 5.4% 
and 4.3% of the control individuals. 
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5.2.1.2 Eight years after diagnosis 
In the 1983 cohort, 11% of patients with diabetes received inpatient care at departments 
of internal medicine and endocrinology compared to 0.9% of the control individuals 
(Table 6). The corresponding figures for the 1999 cohort were 2.8% and 1.0%, 
respectively. Patients with diabetes also made significantly more visits to daycare. 
 
Patients with diabetes had a significantly higher utilisation of all outpatient clinics. For 
example, more patients with diabetes made three or more visits than the control 
individuals. Also, after excluding visits to diabetes clinics, the utilisation of outpatient 
clinics among patients with diabetes was significantly higher. 
 
Patients with diabetes visited nurses more often than the control individuals: 7.3% and 
12% of patients with diabetes, which was significantly more than 4.3% and 5.1% of 
control individuals. 
 
 
5.2.2 Changes in utilisation over time 
To see changes in utilisation patterns among patients with diabetes over time, the 
results from the study in 1991/1993 were compared with the results from this study in 
2007/2009. 
 
5.2.2.1 One year after diagnosis 
There was a significant reduction in the number of visits to departments of internal 
medicine and endocrinology: 49% in the 1992 cohort compared to 4.2% in the 2008 
cohort. The latter figure indicates that the excess use had decreased and was no longer 
significant, but more in line with usage by the control individuals. 
 
5.2.2.2 Eight years after diagnosis 
Visits to departments of internal medicine and endocrinology had decreased to 11% of 
the patients in the 1983 cohort and 2.8% in the 1999 cohort, where the excess use was 
no longer significant (Table 6). However, there was a significant increase in the 
utilisation of daycare. Patients with diabetes in the 1999 cohort reported an 
approximate utilisation rate that was four times higher than the 1983 cohort (44% vs. 
11%). Some of the increase in utilisation of daycare may be explained by the increase 
in visits to diabetes clinics. 
 
 
5.2.3 Diabetes-related utilisation 
Visits to the emergency room and diabetes nurse were similar in all cohorts, but visits 
to dieticians and podiatricians varied according to disease duration. In this section, the 
percentages refer to the patient cohorts in the following order of years after diagnosis: 
1, 8, 15 and 24. 
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TABLE 6. Healthcare utilisation for patients with diabetes (Case) and control individuals (Control) followed-up in four cohorts 1 year and 8 years after diagnosis 
 
 No. of Follow-up 1 year after diagnosis  Follow-up 8 years after diagnosis 
 visits 1992 cohort (1993) 2008 cohort (2009)  1983 cohort (1991) 1999 cohort (2007)   
  Case Control OR 95% CI Case Control OR 95% CI p Case Control OR 95% CI Case Control OR 95% CI p 
  n=237 n=443  n=142 n=256 (case- n=317 n=586 n=217 n=394 (case-
  % %  % % case) % % % % case)
Hospital inpatient care                
All departments 0 31 92    87 92   <0.001 82 91   88 94   0.03
 >1 69 8.4 25 16-38 13 8 1.8 9.90-3.5  18 9.3 2.2 1.5-3.3  12 6 2.2 12-4.0  
Internal medicine/ 0 51 100  96 99  <0.001 89 99  97 99  0.001
Endocrinology >1 49 0.5 211 51-868 4.2 1.2 3.7 0.92-15  11 0.9 14 5.2-35  2.8 1.0 2.8 0.77-9.9  
         
Hospital daycare         
All departments 0 54 85  55 84  0.86 89 96  56 86  <0.001
(incl. diabetes) >1 46 15 4.9 3.4-7.0 45 16 4.2 2.6-4.7  11 4.4 2.7 1.6-4.6  44 14 4.8 3.3-7.1  
         
Hospital outpatient clinics        
All clinics 0 26 82  22 77  0.73 29 81  34 75  0.002
 1-2 57 15 12 8.0-18 60 17 12 7.2-20  57 14 11 8.1-16  42 18 5.1 3.4-7.6  
 >3 17 3.2 17 8.6-32 18 6.3 9.6 4.6-20  15 5.3 7.7 4.6-13  24 6.6 7.8 4.6-13  
         
All non-hospital outpatient contacts       
Physician 0 73 77  81 82  0.09 74 77  71 73  0.44
 >1 27 23 1.2 0.82-1.7 19 18 1.1 0.63-1.8  26 23 1.1 0.82-1.5  29 27 1.1 0.74-1.5  
Nurse 0 86 92  84 95  0.55 88 93  87 93  0.84
 >1 14 8.1 1.8 1.1-3.0 16 5.1 3.6 1.8-7.4  12 7.2 1.8 1.1-2.9  13 7.1 1.9 1.1-3.4  
Hospital inpatient care and daycare during a 1-year period, outpatient visits at hospitals and outpatient contacts outside the hospital during a 3-month period. 
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About 10% of these patients responded that they had visited the emergency room 
because of their diabetes in the last year (11%, 9.2%, 7.0%, and 9.9%). Around 90% 
had visited a diabetes nurse (94%, 88%, 90%, and 89%). Visits to dieticians were more 
common by the patient with a one-year diagnosis (25%) than by other cohorts (10% to 
14%). Visits to a podiatrician were more common with longer disease duration (16%, 
18%, 22%, and 33%). 
 
The National Guidelines for diabetes care in Sweden state that fundus examinations 
should be made yearly for patients with Type 1 diabetes and every other year for 
patients with Type 2 diabetes. Our results showed that between 49% and 82% had their 
eyes examined in the last year. Of these 47%, 71%, 71%, and 78% had fundus 
photographs taken.  
 
 
5.2.4 Gender aspects on utilisation 
Although Study I was not designed for gender analyses, data divided by sex showed 
several significant differences. Approximately twice as many women with diabetes 
visited ophthalmology clinics as men with diabetes in all cohorts except for the 1992 
cohort. The observed excess use of emergency services in the 1992 and 1999 cohorts is 
largely explained by the fact that women with diabetes had three times higher 
utilisation than the control individuals. 
 
 
5.3 EXCESS COSTS 
 
5.3.1 Healthcare utilisation costs 
In all four cohorts, the following categories account for the largest part of total 
healthcare costs for patients with diabetes: hospital outpatient care (58%-65%), daycare 
(13%-20%), and inpatient care (11%-20%). A similar pattern was evident for the 
control individuals. 
 
The excess costs for healthcare utilisation as a percentage of total healthcare costs were 
as follows: 
 
 65% 1 year after diagnosis (31 149 SEK) 
 58% 8 years after diagnosis (25 882 SEK) 
 34% 15 years after diagnosis (15 631 SEK) 
 45% 24 years after diagnosis (25 672 SEK) 
 
Patients with diabetes had significantly higher costs for hospital inpatient care 8 years 
after diagnosis (excess cost=5,159 SEK, p=0.030) compared to the control individuals. 
Significant differences were also found in hospital outpatient care when emergency 
care was both included and excluded (p<0.001). However, the control individuals in the 
1992 cohort reported higher utilisation of daycare and non-hospital outpatient care than 
the patients with diabetes. Thus, their costs were equal to or greater than the costs for 
patients with diabetes. Diabetes-related utilisation of services such as visits to diabetes 
nurses, dieticians, podiatricians and ophthalmologists resulted in an additional average 
annual cost of about 4 200 SEK per patient. 
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Costs were generally higher for women with diabetes compared to men with diabetes. 
The exceptions were emergency care 8 years after diagnosis and total hospital inpatient 
care 24 years after diagnosis; for this care, men incurred higher care costs. A similar 
pattern was found among the control individuals with the exceptions in the costs of 
emergency care 8 and 24 years after diagnosis, in inpatient care 15 years after 
diagnosis, and in daycare 24 years after diagnosis. 
 
 
5.3.2 Costs for glucose-lowering treatment and monitoring 
Of all patients with diabetes, 94% reported they had insulin treatment. The annual 
average costs per patient for glucose-lowering treatment and monitoring were as 
follows: 
 
 20 108 SEK 1 year after diagnosis 
 27 111 SEK 8 years after diagnosis 
 24 680 SEK 15 years after diagnosis 
 24 278 SEK 24 years after diagnosis 
 
In all cohorts, 43%-48% of the costs were attributable to insulin and prefilled insulin 
pens. Comparisons among the four cohorts showed significant differences in costs for 
insulin (p<0.001), syringes and needles (p=0.008), as well as in the costs for insulin 
pumps (p=0.013) and associated materials (p=0.050). Post-hoc tests revealed that these 
differences in most cases were to be found between patients 1 year after diagnosis and 
all other cohorts. 
 
The costs for insulin were generally higher for men than for women. In particular, this 
was true for patients 8, 15 and 24 years after diagnosis. For the patients, 8 and 24 years 
after diagnosis the costs for prefilled insulin pens were significantly higher for men 
than for women (p=0.012 and p=0.001, respectively). One year after diagnosis, the 
costs for syringes and needles were higher among women than men, and 15 and 24 
years after diagnosis the costs for insulin pumps and associated materials were 
significantly higher for women than for men (p=0.005 and p=0.020, respectively). 
 
 
5.3.3 Total direct costs and excess costs 
The total direct costs (healthcare utilisation, and glucose-lowering medications and test 
materials combined) corresponded to a cost ratio of 4.0, 3.8, 2.3 and 2.6 between the 
patients with diabetes and corresponding control individuals for each cohort (1, 8, 15 
and 24 years after diagnosis). The excess costs as a percentage of total direct costs were 
as follows (Table 7): 
 
 75% 1 year after diagnosis (51 258 SEK) 
 74% 8 years after diagnosis (52 994 SEK)  
 57% 15 years after diagnosis (40 311 SEK)  
 61% 24 years after diagnosis (49 949 SEK) 
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TABLE 7. Distribution of excess costs by disease duration (in Swedish crowns, 2009 prices1) 
 
  Diabetes duration 
1 year 1 year 8 years 8 years 15 years 24 years 
1992 cohort 2008 cohort 1983 cohort 1999 cohort 1992 cohort 1983 cohort 
  
Excess 
costs % 
Excess 
costs % 
Excess 
costs % 
Excess 
costs % 
Excess 
costs % 
Excess 
costs % 
Hospital daycare 7803 16 3164 6 1453 7 2751 5 -61 0 2849 6 
Hospital inpatient care 22664 47 2384 5 3906 19 2409 5 1896 5 419 1 
Hospital outpatient care 
(incl emergency care) 8611 18 24664 48 7186 35 20754 39 14110 35 21868 44 
Non-hospital outpatient 
care 572 1 938 2 473 2 -31 0 -314 -1 535 1 
Glucose-lowering 
treatment and 
monitoring 8776 18 20108 39 7731 37 27111 51 24680 61 24278 49 
Total 48426     51258    20749    52994    40311     49949   
1 Estimates from the previous study in the early 1990's have been inflated from 1997 to 2009 year prices using the 
Swedish Consumer Price Index. 
 
 
5.3.4 Comparison with the previous study 
In the previous study conducted in the early 1990s, the cost ratios for the diabetes and 
control groups 1 year and 8 years after diagnosis were estimated at 5.6 and 3.8, 
respectively, compared to 4.0 and 3.8 in the present study. In the intervening years, 
there has been a clear shift from hospital inpatient care to hospital and non-hospital 
outpatient care 1 year after diagnosis (Figure 3). A similar prominent rise in costs for 
hospital and non-hospital outpatient care could be seen 8 years after diagnosis, while 
hospital inpatient care increased, although excess costs decreased slightly. For patients 
in the 1 year and 8 years after diagnosis cohorts, there was also a two-to-threefold 
increase in the costs for glucose-lowering medications, materials and test devices. 
 
The distribution of excess costs 1 year after diagnosis differed between the two studies. 
In 1993, 47% of the excess costs were attributable to hospital inpatient care whereas 
only 5% in 2009 were attributed to such care. In 2009, costs for hospital outpatient 
care, which accounted for 48% of the total costs, was the largest category of costs 
compared to 18% in 1993 (second highest together with treatment costs). Both studies 
showed that 8 years after diagnosis, costs for glucose-lowering treatment costs and 
monitoring were  the highest (37% and 51%, respectively), followed by costs for 
hospital outpatient care (35% and 39%, respectively). There were no apparent gender 
differences in the distribution of these costs. 
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FIGURE 3. Comparison of the distribution of average annual costs for hospital care, outpatient 
care, and treatment and monitoring of blood glucose levels between the two studies 
 
 
5.4 HEALTH-RELATED QUALITY OF LIFE 
Self-assessed health status in relation to disease duration in diabetes patients 1, 8, 15 or 
24 years after diagnosis was analysed using the generic HRQoL instrument EQ-5D. 
 
 
5.4.1 Reported problems in EQ-5D dimensions 
Compared with control individuals, both women and men with diabetes reported 
significantly more problems in the dimension usual activities 1 year after diagnosis 
(p=0.048 and p=0.033, respectively). Eight years after diagnosis, women with 
diabetes reported more problems in the dimension pain/discomfort than the control 
individuals (p=0.050). Fifteen years after diagnosis, women with diabetes reported 
more problems in the dimensions usual activities (p=0.029) and pain/discomfort 
(p=0.013) than the control individuals, and men with diabetes reported more 
problems in the dimension mobility than the control individuals (p=0.033). 
 
Twenty-four years after diagnosis, women reported more problems in the dimensions 
mobility (p=0.049), self-care (p=0.023) and usual activities (p=0.001) than the female 
control individuals. In general, the combined prevalence of moderate and severe 
problems increased in all five dimensions by disease duration for individuals with 
diabetes. However, 15 and 24 years after diagnosis, significant differences were 
found only in the dimensions self-care (p=0.023) and pain/discomfort (p=0.013) 
among women with diabetes and for mobility (p=0.033) and pain/discomfort 
(p=0.012) among men with diabetes. Similar overall patterns were found for control 
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individuals who reported significantly more problems with pain/discomfort among 
women and with mobility and pain/discomfort among men. 
 
 
5.4.2 EQ-5Dindex and EQ VAS score 
Among women, mean EQ-5Dindex was significantly lower for individuals with 
diabetes compared with control individuals 15 and 24 years after diagnosis (Figure 4). 
The comparison of women with diabetes in the different cohorts showed significant 
differences in mean EQ-5Dindex, which was also true for the control individuals. A 
similar pattern was seen for men with diabetes as well as for male control individuals. 
Post-hoc tests could not detect any significant differences among the cohorts for 
women with diabetes, while significant differences were found for men with diabetes 
between the 1983 cohort and all other cohorts.  
 
 
 
FIGURE 4. Mean EQ-5Dindex in individuals with diabetes compared to control individuals by 
disease duration 
 
The comparison (ANOVA) of the cohorts for the different years of disease duration 
found significant differences between the different cohorts of women with diabetes 
(p=0.022), of female control individuals (p= 0.011), of men with diabetes (p=0.002) 
and of male control individuals (p=0.001), respectively. Post hoc tests could not detect 
where the significance for women with diabetes lay. The test, however, showed 
significant differences for men with diabetes between the 1983 cohort and all other 
cohorts (1992, p=0.002; 1999, p=0.007; 2008, p=0.027), for female control individuals 
between the 2008 and 1983 cohorts (p=0.025), and for male control individuals 
between the 1983 cohort compared with the 2008 (p=0.002) and 1999 (p=0.009) 
cohorts.  
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The mean EQ VAS scores were significantly lower for both women and men with 
diabetes compared with control individuals in all cohorts (Figure 5). Comparisons 
showed no differences between the cohorts of women with different diabetes 
duration. This was also true for women in the control population. However, for men 
with diabetes significant differences were found between the different cohorts, which 
was also the case for their control individuals. 
 
 
 
FIGURE 5. Mean EQ VAS scores in individuals with diabetes compared to control individuals 
by disease duration 
 
ANOVA and post hoc tests showed significant differences between the cohorts of men 
with diabetes (p=0.004) which were found between the 1983 cohort and the 2008 
(p=0.020) and 1999 (p=0.028) cohorts. Between the cohorts of male control individuals 
significant differences were found (p<0.001) between the 1983 cohort and all other 
cohorts (1992, p=0.045; 1999, p=0.040; 2008, P<0.001). The post hoc tests could not 
detect any significant differences between the cohorts for women with diabetes or for 
the female control individuals. 
 
 
5.4.3 Variation on health-related quality of life 
The multivariate regression analysis showed similar patterns for both the EQ-5Dindex 
and the EQ VAS score, which were used as health outcomes measures. The model 
showed that sex, diabetes diagnosis, education level, and not being married or 
cohabiting all had significant negative impact on the health outcome measures. This 
negative effect was shown also for disease duration of 8 years for the EQ VAS score 
and disease duration of 15 and 24 years for both the EQ-5Dindex and the EQ VAS 
score. Models were tested that added the independent variables separately, but these 
tests did not significantly impact the final model. 
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5.5 EQUITABLE CARE 
Having diabetes was a significant predictor in all the final models for utilisation and 
SRH (Table 8). However, this condition did not predict dissatisfaction with care 
received. Women, who used more inpatient care, specialist care and primary care, were 
more often dissatisfied with the care they received. Education level was only significant 
in terms of predicting utilisation of primary care and SRH. In the final model, income 
was a significant predictor for all outcome variables except for utilisation of daycare.  
 
Further analysis involved exploration of differences between individuals with diabetes 
and control individuals as far as their use of health care or their SRH were concerned. 
Education level was only a significant predictor of inpatient care or daycare for 
individuals with diabetes. Income level was significant for both individuals with 
diabetes and control individuals for the prediction of use of emergency services. 
However, for the individuals with diabetes the effect was larger. This difference in the 
size of Exp (β) was even larger when examining the utilisation of primary care by 
individuals in the lower income group; such individuals with diabetes were 
approximately 1.5 times as likely as the control individuals to use primary care. Sex as 
predictor of the use of daycare was not significant for the individuals with diabetes, 
whereas as a predictor of the use of emergency services, sex was only significant for 
the individuals with diabetes. In predicting the use of specialist care for individuals 
with diabetes the Exp (β), the effect of sex was 1.5 times greater than that for control 
individuals. For some independent variables, where the interaction variable was 
significant, there were no large differences evident in the association between the 
relevant independent and dependent variables. The explanation may be because of the 
sample size difference in the two groups.  
 
For any variable where marital status and sex were significant, a logistic regression was 
run with a marital status*sex interaction variable to examine whether the variable for 
marital status had a different effect in women and men. This was significant for 
inpatient care, emergency department, and primary care, but not for daycare. Next, for 
those dependent variables where the marital status*sex interaction variable was 
significant, the data file was split according to marital status, and a logistic regression 
for sex was run for both married and unmarried groups to explore these differences. For 
inpatient care, sex was only significant for married respondents (married p<0.001, Exp 
(β) 0.407; unmarried p=0.102, Exp (β) 0.676). For emergency department, sex was not 
significant for either (married p=0.003, Exp (β) 0.709; unmarried p=0.201, Exp (β) 
0.773), and for primary care sex was significant for both with a similar Exp (β) 
(married p<0.001, Exp (β) 0.642; single p=0.003, Exp (β) 0.610).  
 
 
 
 
  35 
 
TABLE 8. Multivariate regression exploring significant predictors for healthcare utilisation, SRH and dissatisfaction for individuals with diabetes and control individuals 
(final models) 
 
Dependent variable Inpatient care  Daycare Specialist Emergency Primary care  Dissatisfaction SRH 
 2df Sig.  2 df Sig. 2 df Sig. 2 df Sig. 2df Sig. 2 df Sig. 2 df Sig.
 67.378 5 <0.001  159.413 2 <0.001 529.173 8 <0.001 69.253 5 <0.001 69.824 6 <0.001 43.937 4 <0.001 201.137 8 <0.001
 Exp (ß) df Sig.  Exp (ß) df Sig. Exp (ß) df Sig. Exp (ß) df Sig.   Exp (ß) df Sig. Exp (ß) df Sig.
Independent 
variables                          
Case/control 0.535 1 <0.001  0.294 1 <0.001 0.113 1 <0.001 0.615 1 0.004 0.838 1 0.098 0.458 1 <0.001
Sex 0.573 1 0.001     0.714 1 0.002 0.646 1 <0.001 0.748 1 0.012
Age (overall)        3 <0.001   3 <0.001
Age category 1        0.519 1 <0.001   0.312 1 <0.001
Age category 2        0.750 1 0.048   0.370 1 <0.001
Age category 3        0.800 1 0.122   0.752 1 0.067
Education level   ns    ns ns ns 1.302 1 0.018 1.504 1 0.002
Income (overall)  3 <0.001     3 <0.001 3 <0.001  3 <0.001 3 <0.001 3 <0.001
Income group 1 3.894 1 <0.001     2.283 1 <0.001 4.926 1 <0.001 2.088 1 <0.001 2.226 1 <0.001 4.362 1 <0.001
Income group 2 2.351 1 0.003     1.355 1 0.051 2.484 1 0.003 1.297 1 0.106 1.254 1 0.192 2.068 1 <0.001
Income group 3 1.906 1 0.031     1.231 1 0.163 1.783 1 0.071 1.051 1 0.76 1.091 1 0.618 1.281 1 0.208
Marital status     ns   0.821 1 0.064           ns      ns            ns
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6 DISCUSSION 
Because of the excess use of healthcare services by patients with diabetes, the excess 
costs were calculated in this research as 40,000 to 50,000 Swedish crowns per patient 
per year with no significant differences among the four cohorts. Costs for care for 
women (in both the diabetes groups and the control groups) were almost double the 
costs for men in most cohorts.  
 
The research confirmed the negative impact of diabetes on patients’ HRQoL. The 
difference from the control individuals increased by disease duration for women with 
diabetes. However, there were no significant differences in EQ-5Dindex between 
individuals with diabetes 1 year after diagnosis and control individuals, which may be 
explained by good management of diabetes care and the relatively quick patient 
adaptation to the disease. 
 
Women used healthcare services more than men did. Individuals with lower education 
levels or lower income levels also used healthcare services more than individuals with 
higher education levels or higher income levels. The former groups also reported lower 
SRH. Individuals at lower income levels and women were more dissatisfied with the 
health care provided. 
 
Compared to a previous study conducted in the early 1990s, excess costs increased 
mainly due to the greater use of insulin pumps and insulin analogues. Utilisation 
patterns for patients with diabetes were stable except for a significant decrease in 
hospital inpatient care 1 year after diagnosis (60% to 13%), and an increase in daycare 
8 years after diagnosis (11% to 44%). The excess costs 1 year after diagnosis were 
similar whereas excess costs 8 years after diagnosis more than doubled, but while the 
largest proportion of costs in 2009 was for hospital outpatient care, 16 years earlier 
most costs were for hospital inpatient care. In line with the results from the previous 
study, the largest proportion of costs 8 years after diagnosis were attributable to insulin 
treatment and monitoring of blood glucose, followed by the costs for hospital outpatient 
care.  
 
 
6.1 PATTERNS OF HEALTHCARE UTILISATION 
A chronic disease like diabetes is quite naturally associated with an increased need for 
healthcare services. The need for healthcare services varies, depending on patients’ 
characteristics (e.g., age, gender, type of diabetes, disease duration and health status). 
The excess use of healthcare services observed in the early 1990s persisted 16 years 
later. The utilisation patterns were relatively stable except for a major decrease in 
inpatient care 1 year after diagnosis and an increase in daycare 8 years after diagnosis. 
Part of this could be attributable to a general shift from inpatient care, as an increase in 
the use of daycare could also be seen among the control individuals. Daycare has also 
been increasingly used in the continuing education on patient self-management of 
diabetes. 
 
Greater knowledge concerning the differences in patterns of healthcare utilisation can 
be valuable for the development of effective management strategies. Efforts have been 
made to move patients towards primary care in order to improve access and reduce 
costs. 
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A new distribution of responsibilities among different personnel categories and levels 
of care was developed early on in Swedish diabetes care (122). An important finding in 
this study was that patients in an early phase of Type 1 diabetes are treated at hospital 
outpatient clinics, suggesting that the National Guidelines for Diabetes Care have had a 
strong impact on the patterns of care (18). Outpatient visits at hospitals were generally 
more common among patients with diabetes compared with the control individuals. In 
addition to regular control schemes, an explanation could be that patients with diabetes 
may be more likely to seek care when problems arise. A similar change in utilisation 
patterns was also seen in a study tracking diabetes-related utilisation although these 
patients were older and had mainly been diagnosed with Type 2 diabetes (123). 
 
The National Guidelines for Diabetes Care (18) recommend yearly fundus 
examinations for patients with Type 1 diabetes and every second year for patients with 
Type 2 diabetes. Although our data showed a higher likelihood of visits to 
ophthalmology clinics among the patients with diabetes than the control individuals, it 
was lower than expected. This could be attributable to the recall period, which was only 
3 months for that question. However, in the complementary set of questions targeted 
only at the individuals with diabetes, only 72% reported having had an eye examination 
during the past year, which is not in line with the recommendations in the guidelines.  
 
The level of use of primary health care had not changed from the situation 16 years 
earlier. Looking at utilisation patterns, nurses in primary health care have been given 
larger responsibilities in terms of diabetes care, and 90% of the Swedish primary care 
units state that they have diabetes-educated nurses and 30% of them work in diabetes 
teams (22). This change is visible in our study, especially among the patients with 
diabetes and among women. The higher utilisation of primary health care among 
women is congruent with previous findings that women tend to use outpatient services, 
especially preventive services, more than men (124-128). 
 
 
6.2 EXCESS COSTS 
It is widely agreed that long-term complications of diabetes account for most of the 
direct costs for diabetes care as well as for the indirect costs (52, 63, 66, 68-71). The 
study by Jonsson et al. (34) revealed that management of diabetes in young and middle-
aged people had created a major economic challenge for the Swedish healthcare system 
even before accounting for the increase in the gravity and frequency of long-term 
complications. This research, however, which did not reveal any increases in direct 
costs 15 or 24 years after diagnosis, may imply that the modern treatment of diabetes 
has had a positive economic effect as far as the cost of long-term complications in the 
original cohorts (1992 and 1983). 
 
The excess costs for medical care were estimated at around 51,000-53,000 SEK per 
patient per year both in the early and later stages of the disease. However, the excess 
costs were lower for the 15 years after diagnosis cohort (around 40,000 SEK). The 
increases in hospital outpatient care and daycare, and decrease in inpatient care over the 
last two decades could explain the reduction in cost ratio 1 year after diagnosis from 5.6 
to 4.0 and the unchanged cost ratio 8 years after diagnosis of 3.8 when comparing the 
two studies. There was no significant difference in excess costs for healthcare 
utilisation among the four cohorts suggesting that the long-term complications seem to 
be low even 15 and 24 years after diagnosis. Our estimates are higher than previous 
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estimates from Swedish studies of populations including individuals with Type 1 and 
Type 2 diabetes (53, 54) as well as estimates from the United Kingdom (48). The 
European estimates are almost half those of the estimates from the United States (49, 
129). 
 
The change in the level of care, which was revealed in Study I, is not only better for 
patients with diabetes but also provides an economic benefit for the hospital as well as 
for the society as a whole. The results indicate a seemingly low prevalence of severe 
long-term complications 15 and 24 years after diagnosis, which may be a result of 
improvements made in the management of diabetes in the last few decades which, as 
suggested by Bolin et al. (53), may have mitigated diabetes-related complications. 
Studies using data DISS have also shown improvements in Swedish diabetes care over 
time (130, 131).  
 
During this 16-year period, there has been a change in the treatment of diabetes with 
more use of insulin analogues, especially long-lasting insulin analogues. There has also 
been a major increase in the use of insulin pumps and associated materials as well as 
short-lasting insulin. This increase has led to a change in the distribution of excess costs 
where medications for treatment and monitoring now account for around 41%-61% of 
the costs compared to 20%-37% in the previous study (34). 
 
 
6.3 HEALTH-RELATED QUALITY OF LIFE 
The self-reported mean EQ VAS score was significantly lower for individuals with 
diabetes in all cohorts of disease duration compared with corresponding control 
individuals. The mean EQ-5Dindex was significantly lower for women (although not 
for men) 15 and 24 years after diabetes diagnosis compared with the average for the 
corresponding female control individuals. 
 
The diagnosis of diabetes, especially Type 1 diabetes, is generally a distressing 
experience for most individuals. For newly diagnosed individuals with diabetes, there 
is an effect in the EQ-5D dimension usual activities as well as in the mean EQ VAS 
score. An assumption in this research was that HRQoL would be negatively affected 
when treatment is in an intensive phase and that the dimension anxiety/depression 
would be significantly affected. However, the results did not support this assumption. 
Furthermore, there was no significant difference at this stage of the disease in EQ-
5Dindex between individuals with diabetes and the corresponding control individuals. 
The fact that the patients in the 2008 cohort reported their HRQoL 1 year after 
disease onset may explain why there was no discernible difference in the EQ-5D 
dimensions compared with the 1999 cohort (8 years after diagnosis) except for the 
higher prevalence of reported problems in the dimension usual activities. It is likely 
that the patients 1 year after diagnosis have accepted the disease and have somewhat 
adapted to the new routines in their daily life. It has been indicated previously that 
although HRQoL decreases at disease onset, it improves within the first year after 
diagnosis to levels comparable to the general population (102). Another possible 
explanation is patient involvement. As patients take more responsibility for 
monitoring their diabetes, they may feel more in control of their lives. 
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Of the EQ-5D dimensions, problems were most prominent in the dimension 
pain/discomfort. Other studies have shown the same results (81, 85, 99, 103, 105, 
132, 133). As stated previously, no significant differences were found in the 
dimension anxiety/depression 1 year after diagnosis between individuals with 
diabetes and control individuals. This was also true among the cohorts 8, 15 or 24 
years after diagnosis. This finding may possibly be explained by the high prevalence 
of problems in the dimension anxiety/depression among the general population also 
in younger age groups (81). The lower levels of EQ-5Dindex and EQ VAS score 
among individuals with diabetes of longer duration, which was observed for both 
women (after 15 years) and men (after 24 years), is consistent with Hart et al.’s (85) 
study that reported an annual decrease in HRQoL by diabetes patients. Although 
women generally tend to rate their HRQoL lower than men (81, 105), it is noteworthy 
that the difference between individuals with diabetes and control individuals 
increased after 15 years for women and after 24 years for men. This finding suggests 
an earlier social stratification in health for women with diabetes compared with 
women in the general population as well as compared with men with diabetes.  
 
The findings that HRQoL is related not only to age but also to the long-term duration of 
diabetes is evident from the widening gap between individuals with diabetes and the 
control individuals in the prevalence of problems on most EQ-5D dimensions over 
time. Pain/discomfort and anxiety/depression are the two EQ-5D dimensions where 
diabetes duration seems to have the most influence. The findings that HRQoL was 
negatively affected the first year after diagnosis may be an effect of intensive 
counselling and treatment efforts in the early stages of diabetes, although with good 
intentions, as this is an abrupt change of the individual’s life situation and perspectives. 
Investments to improve supportive effort in the early phases may have positive effect 
on not only HRQoL but also on the level of costs from a long-term perspective. 
 
 
6.4 EQUITY PERSPECTIVES 
Equity in health implies that resources are distributed and processes are designed in 
ways that are fair and just, while recognising that different population groups have 
different needs and power (87, 88). The finding that women have higher utilisation of 
some sections of the healthcare system more than men is supported by previous 
findings (134-136). This finding may suggest that women, despite their greater 
longevity, have generally poorer health than men. Or it may suggest that women are 
more likely than men to recognise their own health problems and thus to seek help (43).  
 
There was some suggestion in the research that gender and marital status are related as 
far as the utilisation of healthcare services. Among married or cohabiting people, men 
were much less likely to be admitted for inpatient care than women, but men who lived 
alone were more likely to be admitted for inpatient care than women who lived alone. 
Perhaps the partners of married or cohabiting men cared for them at home. It is also of 
interest that income lost its predictive strength related to the utilisation of inpatient care 
while sex gained strength as a predictor. 
 
This research supports previous research (137, 138) that claims that income levels for 
individuals are a strong predictor of high utilisation of all types of health care except 
daycare. Explanations for this finding can either be that those in the lowest income 
group have poorer health than those in the highest income group, or that those in the 
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highest income group are more inclined to use private health facilities. As this study 
was conducted in Sweden, where healthcare is mainly provided by tax-funded facilities 
(139), it seems most likely that a low income is associated with poorer health. Further 
evidence for this conclusion is the fact that the lowest income group was far more 
likely to report less than good SRH. An individual in the lowest income group was also 
more likely to report greater dissatisfaction with health care received. Greater 
utilisation of health care was associated with greater dissatisfaction, which, to some 
extent, supports findings by Ruggeri et al. (140).  
 
In terms of differences between the individuals with diabetes and the control 
individuals, it was particularly noteworthy that the lower income groups with diabetes 
were more likely to use emergency services or primary care services than the control 
individuals. For individuals with diabetes compared to control individuals, sex was a 
far stronger predictor of the use of specialist care. However, sex was not a significant 
predictor for the use of the emergency services by the control individuals whereas it 
was by the individuals with diabetes. That sex is stronger as a predictor for the use of 
specialist diabetes care calls for further concerns about inequity in diabetes care in 
Sweden. These findings indicate that a woman with a chronic disease will be of more 
concerns and more costly for the healthcare system. Swedish diabetes care seems to 
have difficulties meeting the needs of such women (124). 
 
Despite their higher utilisation of healthcare, individuals with diabetes expressed no 
greater dissatisfaction with health care than the control individuals. The possible 
explanations may be that individuals with diabetes think that their healthcare needs are 
being met or that they are satisfied if their diabetes is under some sort of control. 
Usually individuals with diabetes have a long-term relationship with health care that 
requires on-going and appropriate care.  
 
 
6.5 METHODOLOGICAL CONSIDERATIONS 
In this research, it was possible to use the unique registration of cases of diabetes in 
Sweden to compare the different types of healthcare services used by the four cohorts 
(with diabetes of known duration) with control individuals from the general population. 
This study design also allowed nationwide comparisons of HRQoL. The longitudinal 
development of diabetes and its consequences to the individuals and society were 
addressed by separate analyses in the cohorts with disease durations of 1, 8, 15 or 24 
years. 
 
There are advantages and disadvantages with conducting a repeat study using similar 
design and methodology. With 16 years between the two studies, the way questions 
should be phrased may change. However, in order to compare results it is important 
that any rephrasing of questions is done in such a way that comparison is still possible. 
Some questions were, as mentioned previously, removed from the questionnaire as they 
were either outdated or they had not resulted in any useable data in the study from the 
1990s. However, some questions were also added (e.g., the EQ-5D questionnaire). It 
may seem unnecessary to include two instruments that measure HRQoL. However, the 
EQ-5D instrument was added because it may provide more possibilities for 
international comparisons with the results of this research to other studies on diabetes 
patients or other chronically ill individuals, or for comparisons with population studies. 
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Still, SWED-QUAL was retained in the questionnaire in order to make comparisons 
over time. 
 
The low response rate, especially in the 2008 cohort, may be a potential limitation of 
this research. This rate may possibly reflect the generally declining response rates in 
population and patient surveys that Statistics Sweden has also experienced (115). The 
lower education and income levels among the non-responders (both in the diabetes 
group and among the general population groups) may be related to their overall 
poorer health. As a result, this research may have underestimated the actual 
healthcare utilisation and overestimated the HRQoL. However, as these deficiencies 
apply equally to individuals with diabetes and to the control individuals, a non-
differential misclassification bias is implied.  
 
The first three cohorts (1983, 1992 and 1999) were asked explicitly, via the 
questionnaire, for their permission to cross-check with LISA. Such permission was 
automatic for the fourth cohort (2008) because the cover letter with their questionnaire 
stated that, by completing the questionnaire, the responders were permitting this cross-
check. In this latter situation, it is possible that such automatic permission may have 
depressed the response rate. In addition, only two reminders were sent to the 2008 
cohort whereas three reminders were sent to the other cohorts. This reminder situation 
may also have affected the response rate from the 2008 cohort. 
 
The Swedish Surveys of Living Conditions conducted by Statistics Sweden (106) 
guided the construction of the questionnaire (e.g., for wording and recall periods). 
However, those surveys use structured interviews rather than mailed questionnaires as 
in this research. As the sample population consisted of young and middle-aged 
individuals, no difficulties were expected in their comprehension of the mailed 
questionnaire. No answers suggested the responders misunderstood or were confused 
by the questions. One question that potentially could be misunderstood is the difference 
between daycare and outpatient care. Some of the younger individuals in the control 
group may have limited experience with the healthcare system and may therefore have 
difficulties in distinguishing between a daycare stay and an outpatient visit at a hospital.  
 
The inclusion of young people in study populations may be problematic for analyses 
of socio-economic factors, such as education levels, because many young people are 
students. There is also a potential for non-differential misclassification regarding 
marital status for the population under 20 years of age. Such misclassification would 
result in overestimation of the positive effect of marital or cohabitation status because 
many students still live in the family home. Living at home could be comforting for 
younger individuals with diabetes.  
 
Because of its limited scope, this research did not include the costs of prescribed and 
non-prescribed medications other than insulin although there was a significantly higher 
use of both antihypertensive and lipid-lowering medications by the patients with 
diabetes compared to the control individuals. However, had these costs been included, 
excess costs would probably have been even higher. It was also not within the scope of 
this research to include indirect costs such as, for example, leave of absence and early 
retirement. It would be interesting to take a societal perspective in investigating how 
indirect costs are affected by disease duration; it has been shown that a diabetes 
diagnosis affects education level (141) as well as future income (142).  
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An additional constraint of the research was the estimation of unit costs. Although the 
survey gave detailed data on each individual’s use of healthcare services, it was not 
possible to collect data on the costs of care at the individual level. Instead, the unit costs 
were estimated from price lists that may not reflect actual costs for different levels of 
care. However, the estimation of excess costs was still adequate as the same unit costs 
were used for patients with diabetes and for the corresponding control individuals. 
 
The concept of excess costs (i.e., the difference in costs between individuals with 
diabetes and the control individuals) is the central economic concept used in the 
analyses of this research. These excess costs should be interpreted as additional costs 
attributable to diabetes that can be expected in the various stages of disease for the four 
cohorts. Some of these costs are directly related to diabetes, such as treatment and 
monitoring of diabetes, whereas others may be less obvious. For the purposes of the 
analyses, unadjusted data for real-life populations are likely to be more useful than 
adjusted data in standardised trial populations. 
 
It is possible to calculate the economic cost of diabetes in the healthcare system using 
cost ratios applicable to the individuals with diabetes and to control individuals. 
Jonsson et al. (34), in their study, compared cost ratios with those in Selby’s study (68) 
that analysed data from a similar age group in the United States. The cost ratios in the 
two studies were essentially identical although absolute costs of care in the US study 
were higher. Cost ratios could therefore be used to compare healthcare costs by 
different countries even when the structure, organisation and financing of the healthcare 
systems may differ. The research of this study also showed that although costs had 
generally increased during the 16 years after the previous study (34), the cost ratios 
reflected the decrease in the use of inpatient care (see Study I). 
 
The main methodological strengths of the research reported on in this thesis are its use 
of data derived from the large number of survey participants, the chronological data on 
the patients’ onset of diabetes, the various disease durations (1, 8, 15 or 24 years), the 
population-based comparisons, and the comparisons with the previous study. Although 
this study is not truly longitudinal because it does not involve repeated observations of 
the same individuals, the research on the four cohorts with different disease durations 
can still provide useful information on how the duration of diabetes affects healthcare 
utilisation and HRQoL (other than normal ageing). Other strengths of the research are 
its estimation of excess costs at different stages of the disease taking into consideration 
many kinds of healthcare consumption and the costs for treatment and monitoring of 
blood glucose levels. Therefore, the research permitted calculation of direct, diabetes-
related healthcare consumption (which could underestimate the impact of diabetes) and 
of the estimation of real-life consumption in the studied cohorts. 
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7 CONCLUSIONS  
Observational studies of real-life consequences of diabetes are relatively rare, in 
comparison with all clinical trials that address the effectiveness of various interventions 
in patients with diabetes. Observations of the healthcare utilisation in individuals with 
various years of diabetes duration at two different points of time, and comparisons of 
the patterns with the general population samples provide a general overview on how 
developments in diabetes management are associated with the utilisation patterns and 
the excess use of care by patients with diabetes. Thereby, estimation of the costs for 
healthcare utilisation and the treatment and monitoring of diabetes may support rational 
resource allocation in healthcare. 
 
This research has revealed that individuals with diabetes currently are seemingly living 
rather unrestricted lives with less hospital inpatient care and a higher degree of self-
management than 16 years previously. However, the studies in this thesis also indicate 
that healthcare utilisation, costs and HRQoL may vary by gender and socio-economic 
background. In addition to having diabetes, being a women, having a low education 
level or low income, and not being married had a negative effect on almost all outcome 
measures addressed in this thesis.  
 
Continued health services research that describes and analyses utilisation patterns and 
different outcomes of care may be a valuable complement to more clinically oriented 
research. Health services research may also provide valuable information in the 
formulation of future healthcare policies. In contrast to randomised controlled trials, 
follow-up studies of real-life diabetes populations living in real-world health systems 
can shed light on issues of access to the healthcare system as well as on associated 
equity issues.   
 
 
7.1 IMPLICATIONS 
This research increases the knowledge on diabetes care and costs 1 to 24 years after 
diagnosis. As the treatment of diabetes has changed considerably during the last three 
decades, it was important to continue re-examining the medical developments as well 
as their economic implications. As changes in the level of health system services take 
place continuously, repeat studies are important for comparing changes in utilisation 
patterns and for comparing direct costs over time. With information on real-life 
healthcare utilisation, new cost estimates are possible that reflect current treatment 
practices. These estimates can be used in the planning and rational allocation of 
resources in health care. The observed changes reported on in the four studies of this 
thesis probably reflect successive reformation of diabetes care in Sweden and may 
inspire further changes.  
 
However, the four studies suggest that despite efforts to reduce inequalities in health 
care, there is still a need to develop strategies for monitoring the performance of the 
healthcare services from a gender and socio-economic equity point of view. Therefore, 
in planning for reforms or changes in the healthcare system, it is important to 
understand the differences in how these changes may affect women, men and people of 
different socio-economic statuses.   
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